Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Hemispherx BioPharma, Inc    HEB

HEMISPHERX BIOPHARMA, INC (HEB)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2018 | 02:31pm CEST

ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders through the development of its immunology products Ampligen® and Alferon®, today announced its financial results for the first quarter ended March 31, 2018.

“We made significant progress in the quarter that just ended, including significant improvements to our balance sheet, the production of the equivalent of more than 8,500 vials of Ampligen at our contract fill and finish manufacturer, the expansion of our Ampligen supply agreements for early access programs in Canada and Europe under the management of myTomorrows, and the continuation of our plans to start advanced clinical trials of Ampligen as a single agent and a combination immuno-oncology therapy,” said Thomas K. Equels, Hemispherx’s chief executive officer.

“During the quarter we added to our cash by booking Ampligen sales, the sale/leaseback of our manufacturing facility, the sale of non-strategic real estate, and the exercise of warrants and the sale of common stock,” he continued. “We believe that this will enable us to meet the current and anticipated needs of our commercial channels and clinical study programs, as we work with the FDA to identify a path toward approval for Ampligen for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” 

First Quarter 2018 Financial Highlights
As of March 31, 2018, Hemispherx had $4.6 million in cash and cash equivalents, compared to $2.1 million at December 31, 2017. Cash used in operations was $2.5 million for the three months ended March 31, 2018, compared to $3.0 million in the same quarter in 2017. The net loss from operations was $2.7 million, or $0.70 per share, for the first quarter of 2018, compared to a net loss of $2.8 million, or $0.11 per share, for the first quarter of 2017.

About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for the treatment of serious and debilitating disorders. Hemispherx's flagship products include the FDA-approved drug Alferon N Injection® and the Argentina-approved drug rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is a double-stranded RNA being developed for globally important diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Because rintatolimod has not been designated safe and effective by the FDA for general use, it is legally available in the United States only through clinical trials. However, Ampligen® has been approved in Argentina for ME/CFS and the company is working toward legal access in other countries where early access programs exist for serious diseases with unmet medical needs, such as ME/CFS. Ampligen® is the only therapy approved anywhere in the world for ME/CFS. An Ampligen® Early Access Program (EAP) approval has also been obtained for therapeutic use in the Netherlands for pancreatic cancer.

Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contact
Hemispherx Biopharma
Phone Number: 800-778-4042
Email: [email protected] 

Primary Logo


© GlobeNewswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HEMISPHERX BIOPHARMA, INC
05/21HEMISPHERX BIOPHARMA : Reports First Quarter 2018 Financial Results and Provides..
AQ
05/17HEMISPHERX BIOPHARMA : to Present at the 8th Annual LD Micro Invitational
AQ
05/16CORRECTING AND REPLACING : Hemispherx Biopharma Reports First Quarter 2018 Finan..
GL
05/16Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provide..
GL
05/15HEMISPHERX BIOPHARMA INC : Management's Discussion and Analysis of Financial Con..
AQ
05/15HEMISPHERX TO PRESENT AT THE 4TH ANN : BD&L and Investment Forum
AQ
05/14HEMISPHERX TO PRESENT AT THE 4TH ANN : BD&L and Investment Forum
AQ
05/11HEMISPHERX BIOPHARMA : to Present at the 8th Annual LD Micro Invitational
AQ
05/10Hemispherx to Present at the 8th Annual LD Micro Invitational
GL
05/08HEMISPHERX BIOPHARMA : Provides an Update to Stockholders Highlighting Cancer Fo..
AQ
More news
News from SeekingAlpha
05/16Hemispherx Biopharma reports Q1 results 
05/02ROUNDS REPORT : Eleven Train Is Moving Fast While Microcap Hemipherx Experienced.. 
04/20Hemispherx secures private $2.57M capital raise; shares up 4% 
04/02Hemispherx Biopharma reports FY results 
03/09Key events next week - healthcare 
Chart HEMISPHERX BIOPHARMA, INC
Duration : Period :
Hemispherx BioPharma, Inc Technical Analysis Chart | HEB | US42366C3016 | 4-Traders
Managers
NameTitle
Thomas Kenwood Equels Executive Vice Chairman, President & CEO
William M. Mitchell Chairman
Wayne S. Springate Senior Vice President-Operations
Adam Pascale Chief Financial & Accounting Officer
David R. Strayer Chief Scientific Officer & Medical Director
Sector and Competitors
1st jan.Capitalization (M$)
HEMISPHERX BIOPHARMA, INC-11.56%12
GILEAD SCIENCES-5.60%88 639
VERTEX PHARMACEUTICALS4.75%40 003
REGENERON PHARMACEUTICALS-21.45%31 288
GENMAB19.78%11 817
BEIGENE LTD (ADR)97.99%10 337